C4 Therapeutics Inc (NAS:CCCC)
$ 6.09 -0.36 (-5.58%) Market Cap: 429.89 Mil Enterprise Value: 266.75 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 58/100

C4 Therapeutics Inc To Discuss CFT7455 Phase 1 Update Call Transcript

Dec 12, 2023 / 09:30PM GMT
Release Date Price: $2.34 (+98.31%)
Operator

Hello, and welcome to the CFT7455 Phase 1 update investor call. (Operator Instructions)

Please note this event is being recorded. I would now like to hand the call to Courtney Solberg. Please go ahead.

Courtney Solberg C4 Therapeutics;Andrew Hirsch C4
Inc. - Senior Manager of IR

Good afternoon, everyone, and thank you for joining our call to discuss Phase 1 dose escalation clinical data of CFT7455 for the potential treatment of relapse refractory multiple myeloma. We're making forward-looking statements today and Slide 2 contains our legal disclaimer on this matter.

Those presenting on today's call are Andrew Hirsch, our President and CEO; Steve Fisher, our Chief Scientific Officer; and Len Reyno, our Chief Medical Officer. We'll begin the opening remarks and then walk you through our preclinical and dose escalation clinical data of CFT7455 in relapse refractory multiple myeloma.

We will end today's call with a Q&A session. I will now turn the call over to Andrew Hirsch for some introductory remarks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot